These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2231066)

  • 21. Aspirin in the primary prevention of cardiovascular disease.
    Hennekens CH; Buring JE
    Cardiol Clin; 1994 Aug; 12(3):443-50. PubMed ID: 7805078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Tendera M; Howard G
    Am J Cardiol; 2011 Jun; 107(12):1796-801. PubMed ID: 21481826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    Lancet; 1988 Aug; 2(8607):349-60. PubMed ID: 2899772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):3A-13A. PubMed ID: 2903874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.
    Hebert PR; Hennekens CH
    Arch Intern Med; 2000 Nov; 160(20):3123-7. PubMed ID: 11074741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.
    Weisman SM; Graham DY
    Arch Intern Med; 2002 Oct; 162(19):2197-202. PubMed ID: 12390062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
    Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici MG; Mattle HP; Rothwell PM;
    Cerebrovasc Dis; 2009; 27(5):509-18. PubMed ID: 19372653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
    JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
    Matías-Guiu J; Ferro JM; Alvarez-Sabín J; Torres F; Jiménez MD; Lago A; Melo T;
    Stroke; 2003 Apr; 34(4):840-8. PubMed ID: 12649515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force.
    Guirguis-Blake JM; Evans CV; Senger CA; O'Connor EA; Whitlock EP
    Ann Intern Med; 2016 Jun; 164(12):804-13. PubMed ID: 27064410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The aspirin controversy in primary prevention.
    Raju NC; Eikelboom JW
    Curr Opin Cardiol; 2012 Sep; 27(5):499-507. PubMed ID: 22874127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of therapeutic interventions in myocardial infarction. Emphasis on secondary prevention.
    Hinstridge V; Speight TM
    Drugs; 1991; 42 Suppl 2():8-20. PubMed ID: 1718703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators.
    Yasue H; Ogawa H; Tanaka H; Miyazaki S; Hattori R; Saito M; Ishikawa K; Masuda Y; Yamaguchi T; Motomiya T; Tamura Y
    Am J Cardiol; 1999 May; 83(9):1308-13. PubMed ID: 10235086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin in the primary prevention of cardiovascular disease: current knowledge and future research needs.
    Hennekens CH; Dalen JE
    Trends Cardiovasc Med; 2014 Nov; 24(8):360-6. PubMed ID: 25444455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Hankey GJ; Sudlow CL; Dunbabin DW
    Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.